Age-Related Macular Degeneration (AMD). A leading cause of progressive vision loss.

AMD often develops without early symptoms, making awareness, imaging, and timely clinical evaluation essential to preserving sight.

What is AMD?

Age-related macular degeneration (AMD) is a progressive eye disease that can blur one's central vision. It damages the macula, the portion of the retina responsible for sharp, central vision (light-sensitive tissue at the back of the eye). As a leading cause of vision loss in older adults, it often develops silently without early symptoms. While AMD rarely causes complete blindness, it can severely blur the center of the visual field, making essential daily activities like reading, driving, and recognizing faces extremely difficult for patients.

Fundus photo showing retina affected by suspected intermediate AMD with visible confluent drusen.

Why early identification of AMD matters

Since AMD progresses silently, the onset of symptoms can mean that irreversible vision loss has already occurred. Early identification is vital to shift the clinical focus toward proactive monitoring and lifestyle interventions. By addressing controllable risk factors like smoking and diet while ensuring timely referrals to specialists, clinicians can significantly slow disease progression. This sense of urgency is key to preserving patient independence and long-term wellbeing.

How AI supports AMD awareness and care pathways

Our technology leverages a recognized approach to detect signs of disease, utilizing the Beckman Scale to identify suspected intermediate and late-stage AMD. By helping identify patients with AMD, AI transforms a standard scan into a scalable imaging model that broadens access to care. As retinal datasets grow, our longitudinal understanding improves, ensuring high-risk patients are fast-tracked through care pathways for expert clinical evaluation.